Marco Gerling
Overview
Explore the profile of Marco Gerling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moro C, Bozoky B, Geyer N, Engstrand J, Dirix L, Vermeulen P, et al.
BJC Rep
. 2024 Nov;
1(1):19.
PMID: 39516702
No abstract available.
2.
Hamida O, Karlsson F, Lundqvist A, Gerling M, Liu L
Oncoimmunology
. 2024 Jul;
13(1):2372875.
PMID: 38974986
Immune checkpoint inhibitors (ICIs) are linked to diverse immune-related adverse events (irAEs). Rare irAEs surface first in clinical practice. Here, we systematically studied the rare irAE, cytokine-release syndrome (CRS), in...
3.
Moro C, Geyer N, Gerling M
Curr Opin Cell Biol
. 2024 Jan;
86:102315.
PMID: 38181657
Cell competition is a mechanism for cellular quality control based on cell-cell comparisons of fitness. Recent studies have unveiled a central and complex role for cell competition in cancer. Early...
4.
Leduc S, De Schepper M, Richard F, Maetens M, Pabba A, Borremans K, et al.
NPJ Breast Cancer
. 2023 Dec;
9(1):100.
PMID: 38102162
Liver is the third most common organ for breast cancer (BC) metastasis. Two main histopathological growth patterns (HGP) exist in liver metastases (LM): desmoplastic and replacement. Although a reduced immunotherapy...
5.
Moro C, Geyer N, Harrizi S, Hamidi Y, Soderqvist S, Kuznyecov D, et al.
Nat Commun
. 2023 Aug;
14(1):5024.
PMID: 37596278
A perimetastatic capsule is a strong positive prognostic factor in liver metastases, but its origin remains unclear. Here, we systematically quantify the capsule's extent and cellular composition in 263 patients...
6.
Zupancic M, Farrajota Neves da Silva P, Kas Elyas K, Friesland S, Ellingsen Cedero T, Gerling M
Case Rep Oncol
. 2023 Jul;
16(1):525-531.
PMID: 37485017
Chemotherapy-related encephalopathy is a rare but severe side effect of cancer therapy. Few reports exist on the course of encephalopathy due to 5-fluorouracil (5FU)/carboplatin treatment. Here, we report on a...
7.
Liu L, Skribek M, Harmenberg U, Gerling M
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36878533
Immune checkpoint inhibitors (ICIs) are associated with a wide range of immune-related adverse events. As oncological indications for ICIs widen, their rare side effects become increasingly visible in clinical practice...
8.
Moro C, Selvam A, Ghaderi M, Pimenoff V, Gerling M, Bozoky B, et al.
Front Oncol
. 2022 Sep;
12:965182.
PMID: 36059619
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. PDAC has a dismal prognosis and an inherent resistance to cytostatic drugs. The lack of reliable experimental models...
9.
Latacz E, Hoppener D, Bohlok A, Leduc S, Tabaries S, Moro C, et al.
Br J Cancer
. 2022 Jun;
127(6):988-1013.
PMID: 35650276
The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of liver metastases were established in 2017. Since then, numerous studies have applied these guidelines, have further substantiated the...
10.
Bozoky B, Moro C, Strell C, Geyer N, Heuchel R, Lohr J, et al.
Neoplasia
. 2021 Nov;
23(12):1300-1306.
PMID: 34798385
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid tumors. Based on transcriptomic classifiers, basal-like and classical PDAC subtypes have been defined that differ in prognosis. Cells...